Journal List > Korean J Gastroenterol > v.59(3) > 1006921

TOOLS
Kim: Efficacy of Entecavir Treatment in Hepatitis B Virus-related Decompensated Cirrhosis
Editorial
The Korean Journal of Gastroenterology

The Korean Journal of Gastroenterology 2012; 59(3): 203-204.

Published online: 21 March 2012

DOI: https://doi.org/10.4166/kjg.2012.59.3.203

Efficacy of Entecavir Treatment in Hepatitis B Virus-related Decompensated Cirrhosis

Yun Soo Kim

Department of Internal Medicine, Gil Hospital, Gachon University, Incheon, Korea.

Correspondence to: Yun Soo Kim, Department of Internal Medicine, Gachon University Gil Hospital, 1198 Guwol-dong, Namdong-gu, Incheon 405-760, Korea. Tel: +82-32-460-8384, Fax: +82-32-460-3408, kimys@gilhospital.com

Copyright © 2012 The Korean Society of Gastroenterology

(open-access):

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Notes

Financial support: None.

Conflict of interest: None.

References

1. Das K, Das K, Datta S, et al. Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis. Liver Int. 2010. 30:1033–1042.
2. Korean Association for the Study of the Liver. KASL practice guideline for chronic hepatitis B. 2011.
3. Lok ASF, McMahon BJ. Chronic hepatitis B: Update. AASLD practice guidelines. 2009.
4. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009. 50:227–242.
5. Perrillo RP, Wright T, Rakela J, et al. Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology. 2001. 33:424–432.
6. Hann HW, Fontana RJ, Wright T, et al. United States Lamivudine Compassionate Use Study Group. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. 2003. 9:49–56.
7. Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2011. 9:274–276.
8. Kim IS, Mun JI, Koo JH, et al. Entecavir therapy for patients with hepatitis B virus-related decompensated cirrhosis. Korean J Gastroenterol. 2012. 59:224–231.
9. Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002. 123:719–727.
10. Hyun JJ, Seo YS, Yoon E, et al. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int. 2012. 2011. [E-pub ahead of print].
11. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010. 52:176–182.
12. Chang TT, Gish RG, de Man R, et al. BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006. 354:1001–1010.
13. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009. 50:2001–2006.
TOOLS
Similar articles